First-line treatment with pembrolizumab plus axitinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with advanced clear-cell RCC* who had intermediate/poor IMDC** risk classification, according to updated results of the KEYNOTE-426*** study presented at BASCO 2019 Annual Meeting held in Singapore.
Use of menopausal hormone therapy (MHT) was associated with a significantly increased risk of invasive breast cancer, which became progressively greater with longer duration of use, a meta-analysis of worldwide prospective epidemiological studies has shown.
Young Singaporean women are likely to get themselves immunized against human papillomavirus (HPV) with the motivation to protect their own health, positive information about the vaccine and parental encouragement, as reported in a recent qualitative study.
Use of docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and docetaxel) as perioperative therapy in patients with locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma confers superior overall survival benefit compared with the standard of care epirubicin and cisplatin plus fluorouracil or capecitabine (ECF/ECX), according to the results of the open-label phase II/III FLOT4 trial.
Radiation heart dosimetric parameters appear to exert neutral effect on overall survival (OS) in nonsmall cell lung cancer patients undergoing postoperative thoracic radiotherapy (PORT), according to a recent Singapore study.
Use of a water-impermeable, friction-reducing barrier film (BF) may reduce skin toxicity (eg, radiation dermatitis, burning, and pruritus) on high-friction breast regions in women with breast cancer receiving post-lumpectomy adjuvant radiation therapy, according to a study.
Patients with HER2+ breast cancer with disease progression despite ≥2 lines of HER2-directed therapy may improve their progression-free survival (PFS) with the addition of neratinib than lapatinib to capecitabine, according to the phase III NALA* trial.
Priming with durvalumab 2 weeks before neoadjuvant chemotherapy (NACT) significantly improves pathological complete response (pCR) rates in patients with previously untreated early triple-negative breast cancer (TNBC), but only a numerical improvement is shown when the overall cohort of patients who received NACT with or without durvalumab is analyzed.
New drug applications approved by US FDA as of 01 - 15 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.